Uproleselan sodium - GlycoMimetics

Drug Profile

Uproleselan sodium - GlycoMimetics

Alternative Names: GMI-1271

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlycoMimetics
  • Class Antineoplastics; Antithrombotics; Glycolipids; Small molecules
  • Mechanism of Action E-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Deep vein thrombosis
  • Phase I Multiple myeloma; Stem cell mobilisation
  • Preclinical Chronic myeloid leukaemia
  • No development reported Solid tumours

Most Recent Events

  • 13 Jun 2018 Chemical structure information added
  • 30 May 2018 GlycoMimetics establishes CRADA with National Cancer Institute for the development of GMI 1271 in Acute myeloid leukaemia
  • 30 May 2018 GlycoMimetics, in collaboration with National Cancer Institute and Alliance for Clinical Trials in Oncology, plans a pivotal phase III trial for Acute myeloid leukaemia (Combination therapy, Newly diagnosed)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top